Sorin invests US$8 million in mitral valve technology developer
Sorin has decided to invest US$8 million in West Bridgewater, MA-based Cardiosolutions, an early-stage company focused on the development of an innovative percutaneous system to treat patients with moderate-to-severe mitral valve regurgitation. The investment, which also includes an option to acquire the company in the future, will finance on-going product development and clinical testing of the technology.
Cardiosolutionsâ technology consists of a catheter delivery system and an implantable device, the Mitra-Spacer. The device is designed to fill the void created by a dilated valvular annulus or deteriorating valve mechanism. By providing a sealing surface for the leaflets of the diseased mitral valve, the implant reduces the mitral regurgitation in patients. According to Sorin, the "cutting-edge" technology represents a less invasive and percutaneous option for patients who suffer from moderate to severe mitral regurgitation, including a portion of those who have congestive heart failure.